<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887976</url>
  </required_header>
  <id_info>
    <org_study_id>GURN-AA-201-OLE</org_study_id>
    <nct_id>NCT02887976</nct_id>
  </id_info>
  <brief_title>Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201</brief_title>
  <official_title>An Open-label Extension (OLE), Expanded Access Study, to Assess Long-term Safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) With Methylprednisolone (4mg Bid) in Patients Who Completed Study Number CHL-AA-201</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GU Research Network, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Churchill Pharmaceutical LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GU Research Network, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label extension (OLE), expanded access study, to assess long-term safety of
      SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in
      patients who completed study number CHL-AA-201.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label extension (OLE), expanded access study, to assess long-term safety of
      SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in
      patients who completed study number CHL-AA-201. An exploratory endpoint of Improved safety
      from switching from Zytiga (aberaterone Acetate 1000mg(4 x 250 mg qd) to SoluMatrix™
      Abiraterone Acetate 500mg (4 x 125 mg qd) will also be ascertained..
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Month 9</time_frame>
    <description>Safety as determined by adverse events deemed related to experimental treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in incidence of Treatment-Emergent Adverse Events in relation to Core Study</measure>
    <time_frame>Month 9</time_frame>
    <description>Explore if a reduction in adverse events occurs in subjects completing core study originally assigned to Zytiga Abiraterone Acetate plus prednison and switched to SoluMatrix Abiraterone Acetate plus methylprednisolone.,</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SoluMatrix™ Abiraterone Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SoluMatrix™ Abiraterone Acetate</intervention_name>
    <description>SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor</description>
    <arm_group_label>SoluMatrix™ Abiraterone Acetate</arm_group_label>
    <other_name>Yonza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate</description>
    <arm_group_label>SoluMatrix™ Abiraterone Acetate</arm_group_label>
    <other_name>medrol</other_name>
    <other_name>solumedrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained prior to any study-related procedure being performed

          2. Previous, uninterrupted enrollment and treatment in trial number CHL-AA-201.

        Exclusion Criteria:

          1. Progressive disease as ascertained by the investigator using standard-of-care
             evaluations.

          2. CHL-AA-201 D84 blood counts of the following:

               1. Absolute neutrophil count &gt; 1500/µL

               2. Platelets &gt; 100,000/µL

               3. Hemoglobin &gt; 9 g/dL

          3. CHL-AA-201 D84 chemistry values of the following:

               1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 x Upper
                  Limit of Normal (ULN)

               2. Total bilirubin &lt; 1.5 x ULN

               3. Creatinine&lt; 1.5 x ULN

               4. Albumin &gt; 3.0 g/dL

               5. Potassium &gt; 3.5 mmol/L
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tony Romero, MS</last_name>
    <phone>402-697-2229</phone>
    <email>tromero@gucancer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GU Research Network/Wichita Urology Group</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GU Research Network/Urology PC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tony Romero, MS</last_name>
      <phone>402-697-2229</phone>
      <email>tromero@gucancer.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Henning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GU Research Network/Urology Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tony Romero, MS</last_name>
      <phone>402-697-2229</phone>
      <email>tromero@gucancer.com</email>
    </contact>
    <investigator>
      <last_name>Luke Nordquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>September 1, 2016</last_update_submitted>
  <last_update_submitted_qc>September 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Castrate Resistant Prostate Cancer (CRPC)</keyword>
  <keyword>metastatic</keyword>
  <keyword>castrate resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Peer reviewed Journal and/or professional meeting.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

